- Home
- SKYE vs ABVC Comparison
SKYE vs ABVC Comparison
Compare SKYE & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- ABVC
- Stock Information
- Founded
- SKYE 2012
- ABVC 2015
- Country
- SKYE United States
- ABVC United States
- Employees
- SKYE N/A
- ABVC N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- SKYE Health Care
- ABVC Health Care
- Exchange
- SKYE Nasdaq
- ABVC Nasdaq
- Market Cap
- SKYE 46.5M
- ABVC 52.1M
- IPO Year
- SKYE N/A
- ABVC N/A
- Fundamental
- Price
- SKYE $1.46
- ABVC $2.89
- Analyst Decision
- SKYE Strong Buy
- ABVC
- Analyst Count
- SKYE 5
- ABVC 0
- Target Price
- SKYE $14.75
- ABVC N/A
- AVG Volume (30 Days)
- SKYE 456.9K
- ABVC 62.5K
- Earning Date
- SKYE 11-10-2025
- ABVC 11-03-2025
- Dividend Yield
- SKYE N/A
- ABVC N/A
- EPS Growth
- SKYE N/A
- ABVC N/A
- EPS
- SKYE N/A
- ABVC N/A
- Revenue
- SKYE N/A
- ABVC $797,916.00
- Revenue This Year
- SKYE N/A
- ABVC $735.18
- Revenue Next Year
- SKYE N/A
- ABVC N/A
- P/E Ratio
- SKYE N/A
- ABVC N/A
- Revenue Growth
- SKYE N/A
- ABVC 56.52
- 52 Week Low
- SKYE $1.14
- ABVC $0.40
- 52 Week High
- SKYE $5.90
- ABVC $5.48
- Technical
- Relative Strength Index (RSI)
- SKYE 37.63
- ABVC 49.64
- Support Level
- SKYE $1.42
- ABVC $2.77
- Resistance Level
- SKYE $1.60
- ABVC $2.95
- Average True Range (ATR)
- SKYE 0.10
- ABVC 0.15
- MACD
- SKYE 0.08
- ABVC 0.00
- Stochastic Oscillator
- SKYE 34.63
- ABVC 50.00
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.